Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of News

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>

30 April 2014: UCL, H Lundbeck & Nanomerics collaborate to develop drug delivery methods to brain

Nanomerics, the drug delivery company, is embarking on a new EPSRC funded collaborative research project with UCL, Exeter University and the Danish pharmaceutical company H Lundbeck to develop drug delivery methods to the brain. 
More...

21 April 2014: Director of UCL Advances wins Queen’s Award for Enterprise Promotion

Director of UCL Advances and Director of UCL Enterprise Operations, Timothy Barnes, has won the Queen’s Award for Enterprise Promotion.
More...

8 April 2014: Mayor launches MedCity with £4.1m investment

The Mayor of London today launched MedCity, a partnership between UCLPartners, King’s Health Partners, Imperial College AHSC, Oxford, Cambridge and the Greater London Authority, to establish London and the Greater South East as a world-leading cluster for life sciences. More...

4 April 2014: UCL Enterprise welcomes new Corporate Partnerships Manager

UCL Enterprise has welcomed Jim Collins as its new Corporate Partnerships Manager for Arts & Humanities, Laws, and Social & Historical Sciences (SLASH).
More...

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>